SUMMARY Thromboxane B2 (TXB2) is the stable metabolite of thromboxane A2 (TXA2), a potent vasoconstrictor which induces irreversible platelet aggregation. The inhibition of TXA2 by aspirin and other agents has been associated with improved outcome following cerebral ischemia in clinical and laboratory studies. To investigate the relation of TXA2 production to cerebral ischemia, we measured the urinary excretion of TXA2 metabolites in 30 patients with acute cerebral ischemia. Urinary immunoreactive TXB2 for this group of ischemic patients was elevated compared to normals, 1818 ± 344 pg/mg Cr (mean ± SE) vs 880 ± 1 2 2 pg/mg Cr (p < .05). Among various subsets of the ischemic patients, those with severe stroke (2108 ± 536 pg/mg Cr), large vessel disease (1646 ± 335 pg/mg Cr), and cardiogenic stroke (2712 ± 1045 pg/mg Cr) were all significantly elevated. Of the stroke patients, only the males demonstrated this significant elevation. These elevations of urinary immunoreactive TXB2 are consistent with a role for increased platelet activation in the pathogenesis of some forms of cerebral ischemia and suggest that gender differences in arachidonate metabolism may exist for stroke patients. Stroke Vol 16, No 1, 1985 THROMBOXANE A2 (TXA2), a metabolite of arachidonic acid generated during the platelet release action, is a powerful vasoconstrictor that induces irreversible platelet aggregation.
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Stroke Vol 16, No 1, 1985 THROMBOXANE A2 (TXA2), a metabolite of arachidonic acid generated during the platelet release action, is a powerful vasoconstrictor that induces irreversible platelet aggregation. 1 Extensive clinical and animal research has implicated TXA2 in the pathogenesis of cerebral ischemia. Aspirin, an inhibitor of TXA2 formation, has demonstrable efficacy in reducing the risk of stroke in patients, particularly males, with transient ischemic attacks. 2 Additionally, impaired post-ischemic reperfusion, the "no-reflow" phenomenon, can be prevented in experimental animals pre-treated with indomethacin, which also inhibits synthesis of TXA2. 3 Despite its importance, measurements of TXA2 and its metabolites have received little attention in clinical studies of cerebral ischemia.
TXA2 has a half-life of only thirty seconds, and is spontaneously converted into the biologically inactive thromboxane B2 (TXB2). 4 TXB2 has been measured in a variety of clinical entities, particularly in coronary artery disease, where plasma elevations have been reported in coronary vasospasm. 5 However, a major difficulty in evaluating plasma TXB2 values is the necessary distinction between circulating, in vivo TXB2, versus TXB2 resulting from the venepuncture necessary to gather the plasma sample. It has been estimated that normal circulating plasma TXB2 levels are less than 2 pg/ml. 6 In contrast, measurements of urinary TXB2 and its major metabolite 2,3 dinor TXB2 avoid the difficulties inherent in plasma measurements. In a recent study, elevations of urinary TXB2 have been demonstrated in patients with deep vein thrombosis and pulmonary embolism. 7 To assess TXA2 production associated with stroke, we measured urinary im-munoreactive TXB2 in a group of patients with cerebral ischemia.
Methods
We studied patients with signs and/or symptoms of cerebral ischemia of ten days or less duration. All patients were admitted for neurological evaluation to Los Angeles County-University of Southern California Medical Center and received head computerized tomography (CT) scans. All patients with either intracerebral hemorrhage on CT scan, hematuria, or a history of ingestion of aspirin, indomethacin, or other nonsteroidal anti-inflammatory agent two weeks prior to or any time after the neurological event were excluded from the study. No patients were admitted into the study with: 1) evidence of ongoing disease processes, other than stroke, associated with increased platelet activation, i.e., coronary artery insufficiency, 5 thrombophlebitis, 7 pulmonary embolus, 7 and sepsis; 8 2) renal insufficiency (BUN > 25 and/or creatinine > 1.9 mg/dl) which may be associated with diminished platelet production of TXA2; 9 or 3) ingestion of calcium channel blockers or phosphodiesterase inhibitors (which may interfere with TXA2 production) 10 -" within ten days of the ischemic event.
All patients were classified for etiology and extent of their ischemic event. Those patients with a cardiac source for cerebral ischemia, i.e., atrial fibrillation, valvular disease, cardiomegaly, and/or cardiomyopathy, were considered "cardiogenic." Patients were considered to have lacunes if they clinically fit any of the four classic lacunar syndromes, i.e., pure motor hemiparesis, pure sensory stroke, dysarthria-clumsy hand, or ataxic-hemiparesis, and who had CT scans which were either normal or demonstrated lacunes. The remaining patients were presumed to have largevessel occlusive disease. The ischemic events were considered to be transient ischemic attacks if signs and/ or symptoms resolved within 24 hours. The remaining patients were characterized as "mild" or "severe" stroke. The distinction was based on an eight point grading system, with a maximum of 2 points for normal level of consciousness, 1 point for normal sensory Two groups of controls were also evaluated. The first group consisted of healthy volunteers who had no history of ingestion of ASA or other nonsteroidal antiinflammatory agent within 10 days. The second group consisted of neurological inpatients admitted for evaluation of nonvascular processes. Exclusion criteria for this group was similar to that used for the ischemic patients.
Single random urine samples of approximately 15-20 cc were collected and frozen within two hours of voiding. While every effort was made to collect specimens in a uniform manner, some patients had specimens collected by catheterization. Analysis of selected patients and controls has indicated only minor differences in urinary TXB2 levels based on the time and method of urine collection. Urine collection was performed on days that patients had no contrast procedure, as radiographic contrast agents may induce platelet activation.
12 Antiserum with a cross reactivity of 70% to 2,3 dinor -TXB2 was obtained from Dr. Lawrence Levine of Brandeis University and was used in a titer of 1:20,000. This antiserum has additional characteristics as described elsewhere. 13 The urine samples were not pretreated in any special way other than by adding a phosphate buffer to adjust the pH to 6.2. In our procedure, 0.05 ml urine was vortexed with 3 H-TXB2 (about 1500 cpm) and anti-TXB2 serum, for a total volume of 0.125 ml. A second antiserum (0.125 ml of goat anti-rabbit) was added to separate free ligand from bound ligand, and the mixture was incubated overnight at 4°C. Following centrifugation, 0.20 ml of the supernatant was mixed with scintillation fluid and counted. The intra-assay variation was 2% and the inter-assay variation 12%. All samples were assayed in duplicate or quadruplicate. This assay cross-reacts to both TXB2 and the more abundant TXB2 metabolite, 2,3 dinor TXB2. Additional validation procedures included assay of urine samples after addition of TXB2 in amounts of 0.2, 0.5, 1.0, 2.0, and 4.0 ng/ml. There was excellent correlation of measured with predicted results (r = 0.974). Assay of urine samples of different aliquot size (0.050, 0.030, 0.020, 0.010, 0.005, 0.0025 ml brought to 0.050 ml with buffer) also yielded an excellent correlation of measured with predicted results (r = 0.992). Nine of the assays were also assayed using two other antisera ("Los Angeles" antisera and "St. Louis" antisera, described previously 15 ). Correlation of assay results were r = 0.852 and r = .930. Urinary creatinine values were determined by autoanalyzer. Unpaired t-tests and linear correlation coefficients were calculated for data analysis.
Due to the potential for error in using the RIA on unextracted urine, 14 an additional radioimmunoassay procedure was performed on selected patients and normals to determine the extent to which measured immunoreactive TXB2 reflected thromboxane B2. This procedure isolated TXB2 from 2,3 dinor and most of the other TXB2 metabolites. 6 Approximately 1000 cpm of 3 H-TXB2 was added to 10 ml urine samples. The samples were acidified to pH 3.5 with HC1, extracted with ethylacetate (10 ml X 3), dried and subjected to high pressure liquid chromatography (HPLC) on a fatty acid reverse-phase column (Walter Associates, Milford, Mass.) using an isocratic solvent system of water: acetonitrile: benzene: acetic acid (76.7: 23.0: 0.2: 0.1).'*• 16 About one-tenth of the peak fraction was used for radioimmunoassay.
Results
A total of 30 patients were evaluated (table 1), 16 males and 14 females. The average age was 60.7 years and the average time between onset of ischemic symptoms and collection of the specimen was 2.4 days (table 2). There were 15 patient controls, 9 males and 6 females, with an average age of 40.5 years. Their diagnoses included Parkinson's disease, seizure disorder, acute idiopathic polyneuropathy, Bell's palsy, lumbar disc herniation, and viral encephalitis. The 31 normal controls consisted of 15 males and 16 females, with an average age of 36.2.
There was a statistically significant elevation (p < .05) of TXB2 in stroke patients compared to normals (table 3) , 1818 ± 344 pg/mg Cr (mean ± SE) versus 880 ± 122 pg/mg Cr, while patient controls (1070 ± 144 pg/mg Cr) were not significantly different than normals. The stroke patients were further analyzed using the subsets of etiology and severity. Those patients with severe stroke (2108 ± 536 pg/mg Cr) were significantly elevated, while those with TIA (1243 ± 118 pg/mg Cr) and mild stroke (1603 ± 547 pg/mg Cr) were not. Analysis of etiologic subgroups indicated significantly increased excretion of TXB2 among those patients with large vessel disease (1646 ± 335 pg/mg Cr) and cardiogenic stroke (2712 ± 1045 pg/ mg Cr), while no significant elevation was found among those patients with lacunes (508 ± 73 pg/mg Cr).
We then evaluated the TXB2 levels by sex for those groups demonstrating significant elevations. When we compared the stroke patients to normals (table 4), we found the male stroke patients had TXB2 excretion 
TABLE 3 Thromboxane B2 (mean ± SE) for all Patients and Controls
TXB2 pg/mg Cr *T = transient ischemic attack; M = mild stroke; S = severe stroke. tLV = large vessel disease; C = cardiogenic; LA = lacune.
significantly elevated compared to normal males ,2191 ± 588 vs 643 ± 83 pg/mg Cr, while no significant elevation was seen among female stroke patients, 1393 ± 286 vs 1103 ± 211 pg/mg Cr. In addition, among the significantly elevated stroke subsets, i.e., those patients with severe stroke, large vessel disease, and cardiogenic stroke, only the males were significantly elevated: 3180 ± 1081, 1788 ± 613 and 3348 ± 1375 pg/mg Cr, respectively. Several analyses were performed to evaluate a potential relationship between age and TXB2 excretion. There was no significant correlation between age and TXB2 for either stroke patients (r = -.05), patient controls (r = .008), or normals (r = .08). Additionally, among stroke patients age 70 and above (n = 6), age 60-69 (n = 13), age 50-59 (n = 7), and below age 49 (n = 4), TXB2 values were 2481 ± 972, 1164 *Elevated compared to normals p < 0.05. tElevated compared to normals p < 0.01. ± 279, 2011 ± 903, and 2615 ± 1185 pg/mg Cr (mean ± SE), respectively. Among patient controls age 50 and above (n = 4) and below 50 (n = 11), TXB2 levels were 952 ± 266 and 1113 ± 176 pg/mg Cr, respectively. Among normals age 50 and above (n = 7) and below age 50 (n = 24), TXB2 levels were 926 ± 191 and 867 ± 148 pg/mg Cr, respectively. None of the various TXB2 values within any of these three groups demonstrated differences reaching statistical significance.
Results of the immunoreactive TXB2 assay were compared with radioimmunoassay after HPLC isolation of TXB2 for 31 patients and normals. The results for the immunoreactive TXB2 assay were 824 ± 270 pg/ml (mean ± SE) while the HPLC method produced levels of 47 ± 8 pg/ml. There was significant correlation between the two methods (r = .787, p < .01). Additionally, analysis of results from the immunoreac- tive TXB2 assay showed similar results when expressed as pg/mg Cr or pg/ml.
Discussion
Increased platelet activation occurs in association with cerebral ischemic episodes, 1718 and it is likely that the increased excretion of TXB2 in our patients with cerebral ischemia arises from such platelet activity. However, it is unclear whether the platelet activation plays a pathogenic role in cerebral ischemia or is an epiphenomenon. The latter is supported by the observation that experimental cerebral ischemia can induce platelet aggregation. 18 However, increased platelet activation can be demonstrated in some patients months after an ischemic event, suggesting a primary role for platelets in the pathogenesis of some forms of cerebral ischemia. 19 This alteration in platelet function is demonstrable in patients with cardiac embolism and non-cardiogenic stroke, 19 a finding supported by the current study where elevation of TXB2 was found in patients with presumed large vessel occlusive disease and cardiogenic stroke.
The elevation of urinary immunoreactive TXB2 concentration was significant in those patients with severe clinical deficits secondary to cerebral ischemia, while those patients with TIA or mild stroke had no such increase. This supports the experimental evidence indicating a role for TXA2 in functional outcome following stroke. 20 Indomethacin, when combined with drugs that reduce platelet aggregation and hemostasis, i.e., prostacyclin and heparin, promotes recovery of somatosensory evoked potentials in experimental cerebral ischemia; prostacyclin and heparin together, without indomethacin, do not have this effect. 20 In the current study, male patients as a group demonstrated increased excretion of immunoreactive TXB2 while females did not. There has been considerable interest in gender differences in stroke prevention since the finding of the Canadian Cooperative Study that male patients with TIA benefited from aspirin, while females did not.
2 Similar findings were seen in the American aspirin trial, 21 while a more recent study described no gender differences with aspirin treatment. 22 While these conflicting results have yet to be fully explained, it does appear that aspirin is equally effective, in both males and females, as an inhibitor of platelet TXA2. 2324 The findings of the current study are compatible with the hypothesis that thromboxanegenerated platelet activation is more prominent in males than in females with cerebral ischemia. 25 If this proves to be true, then the treatment of cerebral ischemia by inhibiting TXA2 formation may have inherent limitations based on gender.
Thromboxane A2 may originate from sources other than platelets, including the kidney. While TXA2 seems not to be a major arachidonic acid metabolite in normal human brain, 26 we cannot exclude the possibility that the increased TXB2 seen in this study originated from infarcted brain. However, the elevation of urinary immunoreactive TXB2 observed in patients with deep vein thrombosis and pulmonary embolism 7 suggests that the TXB2 findings of the current study reflect platelet activation. In summary, the increased excretion of urinary TXB2 in our patients with cerebral vascular disease supports a role for platelet release of TXA2 in the pathogenesis of some forms of cerebral ischemia. SUMMARY Beta-thromboglobulin (betaTG) and malondialdehyde-like material (MDA-LM) plasma levels were studied in patients affected by transient ischemic attacks (TIA) after 2-4 months from the last episode. BetaTG and MDA-LM values were significantly higher in TIA patients than in 20 controls matched for age. No correlation between MDA-LM and betaTG was seen. This study suggests that in vivo platelet activation and, likely, increase of platelet cyclo-oxygenase activity can be detectable in TIA patients.
Stroke Vol 16, No 1, 1985 PLATELET HYPER AGGREGATION AND high beta-thromboglobulin (betaTG) plasma levels, a sign of in vivo platelet activation, 1 have been reported in patients with transient ischemic attacks (TIA).
2 -3 High plasma levels of malondialdehyde-like material (MDA-LM) have been also found in TIA and stroke patients. 4 The interpretation of these last results is not easy mainly because the origin of plasma MDA-LM is not clear yet. 5 Some Authors have considered this parameter as a sign of platelet activability, 6 i.e. a sign of cyclooxygenase and thromboxane synthetase activities, while other investigators 4 retained that plasma MDA-LM is not necessarily expression of platelet activability since MDA-LM can derive from various tissues 7 and during nonenzymatic autoxidation of polyunsaturated fatty acids. 8 In this preliminary report we describe 20 patients suffering from recurrent TIA, showing along with in vivo platelet activation high values of plasma MDA-LM.
Patients and Method
Twenty patients, (14 males and 6 females, age 37-73 years old) who had a definite episode of acute neurological impairment of vascular origin lasting less 24 hours and leaving no sequelae, 9 have been included in this study. The patients had the last TIA 2-A months before and did not take any drug interfering with platelet function or oxidative process from at least one month. 4 females and 2 males suffered from recurrent TIA; the other patients had only one attack before our investigation. A complete clinical assessment was made, with special regard to such risk factor as diabetes, hypertension, smoking and dislipidaemia. Routinary investigation included ECG, chest-X ray, blood levels of cholesterol, HDL-cholesterol, triglycerides, uric acid, glucose, urea and creatinine. All patients performed an Eco-Doppler investigation of cerebral arteries. Six patients were smokers, four patients were affected by hypertension, three were hypercholesterolemic and one was diabetic. Ten patients showed abnormalities on Eco-Doppler investigation. Six patients did not show any of the above mentioned risk factors or laboratory abnormalities. MDA-LM evaluation was made by Smith's method 10 partially modified by us: venous blood was withdrawn from subjects fasting at least 12 hours, mixed with 0.13 mol/1 Na-citrate in a ratio of 9/1. Platelet poor plasma was obtained after blood centrifugation for 15 min at 2000 x g; plasma MDA-LM was assayed treating 1 ml of platelet poor plasma with 1 ml 20% w/v trichloroacetic acid in 0.6 M HC1. Samples were mixed and centrifuged at 2000 X g for 15 min. 0.3 ml of a pH 7 solution of 0.12 M thiobarbiturate, prepared by dissolving thiobarbituric acid (BDH Chemicals Ltd) in 0.26 M 2-amino-2-hydroxymethyll-3propandiol (Tris), was added to 1.5 ml of supernatant sample. This mixture was boiled for 15 min in a water bath; afterwards it was cooled to room tempera-
